

Table 1. Data of Phase III clinical trials of phentermine and controlled-release topiramate (PHEN/TPM CR)

Study	Duration	Patients	Treatment	Dropout	Weight Loss	≥5%
CONQUER	56 weeks	n=2487 BMI=27-45 kg/m ² High BP, high TG, hyperglycemia, increased WC, T2D=16%	Placebo	Placebo =43%	Placebo =-1.4%	Placebo = 21%
			PHEN/TPM CR	PHEN/TPM CR	PHEN/TPM CR	PHEN/TPM CR
			mid dose	mid dose =31%	mid dose =-8.1%	mid dose = 62%
			PHEN/TPM CR	PHEN/TPM CR	PHEN/TPM CR	PHEN/TPM CR
		full dose	full dose = 36%	full dose = -10.2%	full dose =70%	
SEQUEL	52 weeks	n=676	As in CONQUER	16% of total population	Placebo = -1.8%	Placebo =30%
					PHEN/TPM CR	PHEN/TPM CR
					mid dose = -9.3%	mid dose =75.2%
					PHEN/TPM CR	PHEN/TPM CR
		full dose	full dose = -10.5%	full dose =79.3%		
EQUIP	56 weeks	n=1267 BMI >35 kg/m ² FBG <110 mg/dl TG ≤200 mg/dl BP ≤140/90 mmHg	Placebo	Placebo = 47.1%	Placebo = -1.6%	Placebo = 17.3%
			PHEN/TPM CR	PHEN/TPM CR	PHEN/TPM CR	PHEN/TPM CR
			low dose	low dose =39.0%	low dose = -5.1%	low dose =44.9%
			PHEN/TPM CR	PHEN/TPM CR	PHEN/TPM CR	PHEN/TPM CR
			full dose	full dose =33.6%	full dose = -10.9%	full dose =66.7%
EQUATE	28 weeks	n=756 BMI = 30–45 kg/m ²	Placebo	30% of total population	Placebo =-1.7%	Placebo =16%
			Phentermine 7.5 mg		Phentermine 7.5 mg =-5.5%	PHEN/TPM CR
			Phentermine 15 mg		Phentermine 15 mg =-6.1%	mid dose =62%
			Topiramate CR 46 mg		Topiramate CR 46 mg =-5.1%	PHEN/TPM CR
			Topiramate CR 92 mg		Topiramate CR 92 mg =-6.6%	full dose =66%
			PHEN/TPM CR mid dose		PHEN/TPM CR mid dose =-8.5%	
PHEN/TPM CR full dose		PHEN/TPM CR full dose =-9.2%				

BMI: Body Mass Index, BP: Blood Pressure, TG: Triglycerides, WC: Waist Circumference, T2D: Type 2 Diabetes, FBG: Fasting Blood Glucose, PHEN/TPM CR: Phentermine/Topiramate Controlled Release.

‘Low dose’ = phentermine 3.75mg/topiramate 23mg per day. ‘Mid dose’ = phentermine 7.5mg/topiramate 46mg per day. ‘Full dose’ = phentermine 15mg/topiramate 92mg per day.